FDA approves pioneering breast cancer drug that nips resistance in the bud
Nature Biotechnology, Published online: 16 September 2026; doi:10.1038/s41587-026-03333-8 A breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA is one of a wave of new drugs developed to tackle resistance to estrogen-receptor-targeted therapies.
The FDA has approved a new combination regimen from Eli Lilly for certain breast cancer patients. This regimen includes Lilly's oral selective estrogen receptor degrader (SERD) drug Inluriyo. According to Endpoints News, the approval is for second-line breast cancer therapy.
The approval is for patients with metastatic breast cancer.
There is no additional information in the reports to provide further details on the regimen or its usage.
Brief written by urgent.news from Endpoints News, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
